Core Viewpoint - Sanofi's new lipid-lowering drug, Praluent (alirocumab injection), will cease promotion and gradually exit the Chinese market due to global supply issues and strategic adjustments in the cardiovascular market [1][2]. Group 1: Product and Market Dynamics - Praluent was approved in China in December 2019 for the prevention of cardiovascular events in adults with atherosclerotic cardiovascular disease (ASCVD) and for lowering LDL cholesterol in patients with primary hypercholesterolemia [2]. - The drug was included in the National Medical Insurance catalog in 2021, with its price reduced from 1982 yuan to 306 yuan per injection, a decrease of over 80% [2]. - Despite its initial success, Praluent faced intense competition from domestic PCSK9 inhibitors, leading to its decision to exit the market [2][4]. Group 2: Competitive Landscape - The Chinese PCSK9 market is expected to exceed 10 billion yuan by 2030, with multiple domestic competitors entering the space [5]. - Currently, there are seven approved PCSK9 products in China, with four being domestic drugs. Following Praluent's exit, the remaining six products will compete for market share [5][6]. - Competitors like Amgen's Repatha and Novartis' Leqvio have shown strong market performance, with Leqvio achieving sales of $333 million in the first half of 2024 [6]. Group 3: Future Opportunities - The exit of Praluent presents an opportunity for domestic pharmaceutical companies to expand their market share and accelerate product promotion [7]. - Analysts suggest that the competition will drive innovation, leading to the development of more effective and affordable lipid-lowering products [7]. - The stock prices of domestic companies, such as Jingxin Pharmaceutical, have risen in response to Praluent's withdrawal, indicating investor confidence in the potential for domestic alternatives [7].

Core Viewpoint - Sanofi is rapidly filling its cardiovascular product pipeline through acquisitions while planning to exit the Chinese market for its cholesterol-lowering drug, Praluent (alirocumab) due to increased competition from domestic PCSK9 inhibitors and supply challenges [1][2][4]. Group 1: Market Strategy - Sanofi is optimizing its cardiovascular market strategy by discontinuing the promotion of Praluent in China, which is influenced by the inclusion of more domestic PCSK9 inhibitors in the National Medical Insurance Drug List by 2025 [1][2]. - The company confirmed the exit of Praluent from the Chinese market, citing both competitive and supply chain challenges [1][4]. Group 2: Product Pipeline - Sanofi has acquired rights to develop and commercialize the investigational drug, Patisiran sodium injection, in Greater China, which targets conditions like familial chylomicronemia syndrome and severe hypertriglyceridemia [5]. - Earlier, Sanofi also announced the acquisition of exclusive rights to develop and commercialize Aficamten in Greater China, a new generation selective small molecule cardiac myosin inhibitor [5].